| Name | Title | Contact Details |
|---|
Curaleaf Holdings, Inc. is the leading vertically integrated multi-state cannabis operator in the United States.The company is positioned in highly populated, limited license states, and currently operates in 12 states with 44 dispensaries, 12 cultivation sites and 11 processing sites.
Staffed by industry experts, Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech`s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Manufacturing—including development, Compliance, Regulatory, and Validation. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area. Our Culture: At Pharmatech Associates, our mission is to fulfill customer expectations throughout the development and execution of tailored, high value, innovation solutions. We are committed to fostering an environment that is professional and forth right. These principles are captured in the values we believe are essential to maintaining our supportive culture and our commitment to our clients` success. We seek to establish an atmosphere of openness, objectivity, accountability, mutual respect and teamwork so each employee can realize their fullest potential for personal and professional growth. We value work life balance. At Pharmatech talent matters, and we tackle each project with a “no fear” attitude. We stand together as a team, and we`ve got your back. Pharmatech`s commitment to integrity is unwavering.
Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.
ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.